Bicara Therapeutics BCAX Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's preferred stock, par or stated value per share?
- Bicara Therapeutics (BCAX) reported preferred stock, par or stated value per share of $0 in Q1 2026.
- How has Bicara Therapeutics's preferred stock, par or stated value per share changed year-over-year?
- Bicara Therapeutics's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Bicara Therapeutics's preferred stock, par or stated value per share?
- Over 2 years (2023 to 2025), Bicara Therapeutics's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.